Journal article
Abstract RF1-02: Palbociclib plus letrozole versus weekly paclitaxel, both in combination w/ trastuzumab plus pertuzumab, as neoadjuvant treatment for patients w/ HR /HER2 early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)
Luca Malorni, S Tyekucheva, C Zamagni, U Hasler-Strub, A Gombos, C Chakiba-Brugère, M Colleoni, A Mueller, AM Minisini, D Taylor, JP Salmon, E Gallerani, A Cariello, A Fontana, H Roschitzki-Voser, R Kammler, B Ruepp, S Loi, G Viale, MM Regan Show all
Clinical Cancer Research | American Association for Cancer Research (AACR) | Published : 2025
Abstract
Abstract Background: HR+/HER2+ breast cancer (BC) is a biologically heterogeneous group characterized by low pathological complete response (pCR) to chemotherapy combined with anti-HER2 therapy and relative endocrine resistance in the neoadjuvant setting. CDK4/6 inhibitors (CDK4/6i) have recently shown potential for chemotherapy de-escalation when combined with endocrine and anti-HER2 therapy. Methods: TOUCH is an international, open-label, phase II trial for post-menopausal patients (pts) with cT>1 cm, cN0 or cN1, HR+/HER2+ BC, randomized 1:1 to Paclitaxel (T) 80 mg/m2 iv on day 1,8,15 q28d for 4 cycles (arm A) or Palbociclib (Pal) standard dose/schedule for 4 cycles plus ..
View full abstract